Should young patients with high-risk multiple myeloma be offered allogeneic transplants? A vote in favour

Abstract

The prognosis of patients with multiple myeloma has improved markedly over the last two decades. Despite that, allogeneic hematopoietic stem cell transplantation remains the only treatment option with curative potential. There­fore it should be considered for younger patients, especially those with high-risk disease as defined based on revised international scoring system. A decision to use transplantation, as well as the choice of conditioning regimen should be personalized, taking into account a particular center’s experience.